Last reviewed · How we verify
NCT07244289
Managed Access Programs for VAY736, Ianalumab
trial testing ianalumab in Primary Immune Thrombocytopenia. Available.
Quick facts
| Lead sponsor | Novartis Pharmaceuticals |
|---|---|
| Status | AVAILABLE |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- ianalumab — full drug profile →
Conditions studied
- Primary Immune Thrombocytopenia — all drugs for Primary Immune Thrombocytopenia →
- Sjögren's Syndrome — all drugs for Sjögren's Syndrome →
Sponsor
Novartis Pharmaceuticals — full company profile →
Who can join
18 and older, any sex, with Primary Immune Thrombocytopenia or Sjögren's Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this registration is to list Managed Access Programs (MAPs) related to VAY736, ianalumab
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07244289
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ianalumab
Trials testing the same drug.
- NCT07421167 — A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC · Phase 2 · not yet recruiting
- NCT06411639 — Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases · Phase 1 · withdrawn
- NCT05624749 — Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SI · Phase 3 · active not recruiting
- NCT03574545 — Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis · Phase 1 · completed
Other recruiting trials for Primary Immune Thrombocytopenia
Currently open trials in the same condition.
- NCT07039422 — Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (w · Phase 2 · recruiting
- NCT06531018 — Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia. · Phase 1, PHASE2 · recruiting
- NCT06686927 — Study on Glucocorticoid Combined With Gamma Globulin and Ropristine N01 in Treatment of Initial Severe ITP · Phase 2 · recruiting
- NCT06594146 — Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP) · Phase 2 · active not recruiting
- NCT06658834 — A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP · Phase 2 · recruiting
Other Novartis Pharmaceuticals trials
Trials by the same sponsor.
- NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
- NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
- NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
- NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
- NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07244289 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
- Last refreshed: 23 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07244289.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing